β2-Adrenergic Receptor Genotype and Survival Among Patients Receiving β-Blocker Therapy After an Acute Coronary Syndrome

Open Access
Publisher Website
Google Scholar
Abstract
Cardiovascular disease, including acute coronary syndromes (ACS), is the major cause of morbidity and mortality in the Western world.1 Acute and long-term therapy with β-adrenergic antagonists (β-blockers) has become a standard of post-ACS care.2,3 Therapy with β-blockers has been shown to reduce infarct size4 and mortality5,6 among myocardial infarction (MI) patients, most likely by decreasing cardiac energy requirements7 and modifying arrhythmic risk.5,8 Based on multiple clinical trials and guidelines, it has also been used as an important marker of health care quality.9,10 Yet clinical trials report the benefits for groups of patients, and it is quite possible that an ”average” benefit may result from some subgroups of patients deriving substantial benefit, while others derive little benefit from therapy.

This publication has 21 references indexed in Scilit: